Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value

Open access

Abstract

Background: The PNPLA3 p.I148M impact on fat accumulation can be modulated by nutrients. Niacin (Vitamin B3) reduced triglycerides synthesis in in vitro and in vivo NAFLD models. Objectives: In this study, we aimed to investigate the niacin-I148M polymorphism crosstalk in NAFLD patients and examine niacin’s beneficial effect in reducing fat by exploiting hepatoma cells with different PNPLA3 genotype. Design: We enrolled 172 (Discovery cohort) and 358 (Validation cohort) patients with non-invasive and histological diagnosis of NAFLD, respectively. Dietary niacin was collected from food diary, while its serum levels were quantified by ELISA. Hepatic expression of genes related to NAD metabolism was evaluated by RNAseq in bariatric NAFLD patients (n = 183; Transcriptomic cohort). Hep3B (148I/I) and HepG2 (148M/M) cells were silenced (siHep3B) or overexpressed (HepG2 I148+) for PNPLA3, respectively. Results: In the Discovery cohort, dietary niacin was significantly reduced in patients with steatosis ≥ 2 and in I148M carriers. Serum niacin was lower in subjects carrying the G at risk allele and negatively correlated with obesity. The latter result was confirmed in the Validation cohort. At multivariate analysis, the I148M polymorphism was independently associated with serum niacin, supporting that it may be directly involved in the modulation of its availability. siHep3B cells showed an impaired NAD biosynthesis comparable to HepG2 cells which led to lower niacin efficacy in clearing fat, supporting a required functional protein to guarantee its effectiveness. Conversely, the restoration of PNPLA3 Wt protein in HepG2 I148+ cells recovered the NAD pathway and improved niacin efficacy. Finally, niacin inhibited de novo lipogenesis through the ERK1/2/AMPK/SIRT1 pathway, with the consequent SREBP1-driven PNPLA3 reduction only in Hep3B and HepG2 I148M+ cells. Conclusions: We demonstrated a niacin-PNPLA3 I148M interaction in NAFLD patients which possibly pave the way to vitamin B3 supplementation in those with a predisposing genetic background.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnut.2023.1101341

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 The PNPLA3 I148M variant affects alimentary and serum niacin levels in the discovery cohort. (A,B) Niacin intake was reduced in NAFLD patients with steatosis ≥ 2 and PNPLA3 CG/GG mutation at bivariate analysis (*p < 0.05 at Wilcoxon test, vs steatosis < 2 and vs PNPLA3 CC). (C) Circulating niacin levels were lower in PNPLA3 I148M carriers at bivariate analysis compared to non-carriers (*p < 0.05 at Wilcoxon test). (D) Negative correlation between serum niacin concentration and body mass index (BMI). (E,F) Bivariate analysis shows the trend of dietary niacin intake in NAFLD patients stratified according to both the PNPLA3 G at-risk allele and obesity. In panel (F), NAFLD patients were even subcategorized by the presence of steatosis < 2 and steatosis ≥ 2. (G,H) The PNPLA3 at-risk genotype affected niacin absorption in a subgroup of obese NAFLD subjects and with steatosis ≥ 2 (p = 0.005 at ANOVA, *p < 0.05 vs BMI < 30 CC; p = 0.04 at ANOVA, *p < 0.05 vs steatosis ≥ 2 with BMI < 30 CC).
FIGURE 1 The PNPLA3 I148M variant affects alimentary and serum niacin levels in the discovery cohort. (A,B) Niacin intake was reduced in NAFLD patients with steatosis ≥ 2 and PNPLA3 CG/GG mutation at bivariate analysis (*p < 0.05 at Wilcoxon test, vs steatosis < 2 and vs PNPLA3 CC). (C) Circulating niacin levels were lower in PNPLA3 I148M carriers at bivariate analysis compared to non-carriers (*p < 0.05 at Wilcoxon test). (D) Negative correlation between serum niacin concentration and body mass index (BMI). (E,F) Bivariate analysis shows the trend of dietary niacin intake in NAFLD patients stratified according to both the PNPLA3 G at-risk allele and obesity. In panel (F), NAFLD patients were even subcategorized by the presence of steatosis < 2 and steatosis ≥ 2. (G,H) The PNPLA3 at-risk genotype affected niacin absorption in a subgroup of obese NAFLD subjects and with steatosis ≥ 2 (p = 0.005 at ANOVA, *p < 0.05 vs BMI < 30 CC; p = 0.04 at ANOVA, *p < 0.05 vs steatosis ≥ 2 with BMI < 30 CC).CC BY · PubMed Central
FIGURE 2 Obesity heightens PNPLA3 genetic risk on niacin absorption in the validation cohort. (A) Negative correlation between serum niacin concentration and body mass index (BMI). (B,C) The presence of the PNPLA3 I148M variant combined with obesity reduced niacin absorption in biopsied NAFLD subjects, independently of steatosis severity (p = 0.004 at ANOVA, *p < 0.05 vs PNPLA3 CG/GG with/without obesity and vs PNPLA3 CC with BMI ≥ 30). p = 0.0001 at ANOVA, **p < 0.01 vs. PNPLA3 CG/GG without obesity.
FIGURE 2 Obesity heightens PNPLA3 genetic risk on niacin absorption in the validation cohort. (A) Negative correlation between serum niacin concentration and body mass index (BMI). (B,C) The presence of the PNPLA3 I148M variant combined with obesity reduced niacin absorption in biopsied NAFLD subjects, independently of steatosis severity (p = 0.004 at ANOVA, *p < 0.05 vs PNPLA3 CG/GG with/without obesity and vs PNPLA3 CC with BMI ≥ 30). p = 0.0001 at ANOVA, **p < 0.01 vs. PNPLA3 CG/GG without obesity.CC BY · PubMed Central
FIGURE 3 The PNPLA3 G allele impairs hepatic NAD metabolism in the transcriptomic cohort independently of steatosis severity. (A–C) Hepatic NAPRT1 mRNA levels were reduced in the presence of the PNPLA3 CG/GG mutation (**p < 0.01 at Wilcoxon test vs PNPLA3 CC), while NADSYN1 and NMNAT1 expression were upregulated in PNPLA3 CG/GG carriers (*p < 0.05 at Wilcoxon test vs PNPLA3 CC). (D–F) Hepatic NAPRT1, NADSYN1, and NMNAT1 expression were modulated in response to PNPLA3 CG/GG mutation, but regardless of steatosis grade (NAPRT1: p = 0.0004 at ANOVA, **p < 0.01 vs PNPLA3 CC with steatosis < 2; *p < 0.05 vs PNPLA3 CC with steatosis ≥ 2; NADSYN: p = 0.0001 at ANOVA, *p < 0.05 vs PNPLA3 CC with steatosis < 2 and ≥ 2; NMNAT1: p = 0.0001 at ANOVA, **p < 0.01 PNPLA3 CC with steatosis < 2, *p < 0.05 vs PNPLA3 CC with ≥ 2). (G–L) The mRNA levels of NAD-utilizing complexes (MDH1/2. IDH3B, PDHA1/B and OGDB) were decreased in presence of the PNPLA3 G at-risk allele (*p < 0.05 and **p < 0.01 at Wilcoxon vs PNPLA3 CC).
FIGURE 3 The PNPLA3 G allele impairs hepatic NAD metabolism in the transcriptomic cohort independently of steatosis severity. (A–C) Hepatic NAPRT1 mRNA levels were reduced in the presence of the PNPLA3 CG/GG mutation (**p < 0.01 at Wilcoxon test vs PNPLA3 CC), while NADSYN1 and NMNAT1 expression were upregulated in PNPLA3 CG/GG carriers (*p < 0.05 at Wilcoxon test vs PNPLA3 CC). (D–F) Hepatic NAPRT1, NADSYN1, and NMNAT1 expression were modulated in response to PNPLA3 CG/GG mutation, but regardless of steatosis grade (NAPRT1: p = 0.0004 at ANOVA, **p < 0.01 vs PNPLA3 CC with steatosis < 2; *p < 0.05 vs PNPLA3 CC with steatosis ≥ 2; NADSYN: p = 0.0001 at ANOVA, *p < 0.05 vs PNPLA3 CC with steatosis < 2 and ≥ 2; NMNAT1: p = 0.0001 at ANOVA, **p < 0.01 PNPLA3 CC with steatosis < 2, *p < 0.05 vs PNPLA3 CC with ≥ 2). (G–L) The mRNA levels of NAD-utilizing complexes (MDH1/2. IDH3B, PDHA1/B and OGDB) were decreased in presence of the PNPLA3 G at-risk allele (*p < 0.05 and **p < 0.01 at Wilcoxon vs PNPLA3 CC).CC BY · PubMed Central
FIGURE 4 PNPLA3 loss-of-function dampens NAD synthesis in hepatocytes after niacin administration. (A,B) PNPLA3 mRNA and protein levels were assessed by qRT-PCR and Western blot, respectively, in hepatoma cells. (C) NAD content was assessed in Hep3B, siHep3B, HepG2 and HepG2I148+ cells through NAD/NADH Colorimetric/Fluorometric Assay Kit at both baseline and after niacin exposure. (D–F) NAPRT1, NADSYN and NMNAT1 mRNA levels evaluated by qRT-PCR in hepatoma cells (Hep3B, siHep3B, HepG2 and HepG2I148+) with or without niacin treatment. For gene expression, data were normalized to ACTB housekeeping gene and expressed as fold increase (Arbitrary Unit-AU) compared to control group. For Western blot, data were normalized to vinculin housekeeping protein and expressed as fold increase (AU) compared to control group. For violin plot, data were expressed as median concentration (thick dashed lines) and interquartile range (dotted lines). Adjusted *p < 0.05 and **p < 0.01.
FIGURE 4 PNPLA3 loss-of-function dampens NAD synthesis in hepatocytes after niacin administration. (A,B) PNPLA3 mRNA and protein levels were assessed by qRT-PCR and Western blot, respectively, in hepatoma cells. (C) NAD content was assessed in Hep3B, siHep3B, HepG2 and HepG2I148+ cells through NAD/NADH Colorimetric/Fluorometric Assay Kit at both baseline and after niacin exposure. (D–F) NAPRT1, NADSYN and NMNAT1 mRNA levels evaluated by qRT-PCR in hepatoma cells (Hep3B, siHep3B, HepG2 and HepG2I148+) with or without niacin treatment. For gene expression, data were normalized to ACTB housekeeping gene and expressed as fold increase (Arbitrary Unit-AU) compared to control group. For Western blot, data were normalized to vinculin housekeeping protein and expressed as fold increase (AU) compared to control group. For violin plot, data were expressed as median concentration (thick dashed lines) and interquartile range (dotted lines). Adjusted *p < 0.05 and **p < 0.01.CC BY · PubMed Central
FIGURE 5 (A) Evaluation of LDs formation was assessed in hepatoma cells (Hep3B, siHep3B, HepG2, and HepG2I148+) after PA challenge and NIA treatment by ORO staining (100× magnification). Nuclei were counterstained by hematoxylin. (B) TG content was measured in cell lysates (Hep3B, siHep3B, HepG2, and HepG2I148+) through Triglycerides Colorimetric/Fluorometric Assay Kit. (C) DGAT2 mRNA levels were quantified in hepatoma cells with or without niacin treatment after PA challenge (Hep3B, siHep3B, HepG2, and HepG2I148+) by qRT-PCR. For gene expression, data were normalized to ACTB housekeeping gene and expressed as fold increase (Arbitrary Unit-AU) compared to control group. For violin plot, data were expressed as median concentration (thick dashed lines) and interquartile range (dotted lines). Adjusted *p < 0.05 and **p < 0.01.
FIGURE 5 (A) Evaluation of LDs formation was assessed in hepatoma cells (Hep3B, siHep3B, HepG2, and HepG2I148+) after PA challenge and NIA treatment by ORO staining (100× magnification). Nuclei were counterstained by hematoxylin. (B) TG content was measured in cell lysates (Hep3B, siHep3B, HepG2, and HepG2I148+) through Triglycerides Colorimetric/Fluorometric Assay Kit. (C) DGAT2 mRNA levels were quantified in hepatoma cells with or without niacin treatment after PA challenge (Hep3B, siHep3B, HepG2, and HepG2I148+) by qRT-PCR. For gene expression, data were normalized to ACTB housekeeping gene and expressed as fold increase (Arbitrary Unit-AU) compared to control group. For violin plot, data were expressed as median concentration (thick dashed lines) and interquartile range (dotted lines). Adjusted *p < 0.05 and **p < 0.01.CC BY · PubMed Central
FIGURE 6 The PNPLA3-niacin crosstalk may occur via ERK1/2/AMPK/SIRT1 pathway. (A–C) Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204), p44/42 MAPK (ERK1/2), Phospho-AMPK and AMPK protein levels were evaluated by Western blot in hepatoma cells (Hep3B, siHep3B, HepG2 and HepG2I148+) after PA challenge and niacin treatment. (D–H) SIRT1, ACC, FASn, SREBP1 and PNPLA3 mRNA levels were assessed in hepatoma cells by qRT-PCR. (I) Schematic figure of the putative interplay between the canonical pathway of NAD biosynthesis, which is dependent of niacin availability, and PNPLA3 genotype. For gene expression, data were normalized to ACTB housekeeping gene and expressed as fold increase (Arbitrary Unit-AU) compared to control group. For Western blot, data were normalized to vinculin housekeeping protein and expressed as fold increase (AU) compared to control group. Adjusted *p < 0.05 and **p < 0.01.
FIGURE 6 The PNPLA3-niacin crosstalk may occur via ERK1/2/AMPK/SIRT1 pathway. (A–C) Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204), p44/42 MAPK (ERK1/2), Phospho-AMPK and AMPK protein levels were evaluated by Western blot in hepatoma cells (Hep3B, siHep3B, HepG2 and HepG2I148+) after PA challenge and niacin treatment. (D–H) SIRT1, ACC, FASn, SREBP1 and PNPLA3 mRNA levels were assessed in hepatoma cells by qRT-PCR. (I) Schematic figure of the putative interplay between the canonical pathway of NAD biosynthesis, which is dependent of niacin availability, and PNPLA3 genotype. For gene expression, data were normalized to ACTB housekeeping gene and expressed as fold increase (Arbitrary Unit-AU) compared to control group. For Western blot, data were normalized to vinculin housekeeping protein and expressed as fold increase (AU) compared to control group. Adjusted *p < 0.05 and **p < 0.01.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 15

Metadata

Authors
Paolini, E., Longo, M., Meroni, M., Tria, G., Cespiati, A., Lombardi, R., Badiali, S., Maggioni, M., Fracanzani, A. L., & Dongiovanni, P.
Affiliations
  • University of Milan (IT)
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
Corresponding author
Dongiovanni, Paola
Venue
Frontiers in Nutrition
Published
2023-03-02
Volume
10
Pages
1101341-1101341
ISSN
2296-861X (ISSN-L)
OpenAlex
W4322769950
Cited by
11
References
40
Citations by year
2026: 3 · 2025: 2 · 2024: 4 · 2023: 2
FWCI
2.20
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Nutrition (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Ministero della Salute
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Nutrition, Genetics, and Disease
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
PNPLA3, I148M polymorphism, nicotinic acid, non-alcoholic fatty liver disease, genetic screening, NAD+ metabolism, hepatic steatosis, de novo lipogenesis, SREBP1, dietary niacin, obesity, hepatocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value. https://app.cochat.ai/papers/10.3389/fnut.2023.1101341
The paper
Paolini, E., Longo, M., Meroni, M., Tria, G., Cespiati, A., Lombardi, R., Badiali, S., Maggioni, M., Fracanzani, A. L., & Dongiovanni, P. (2023). The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2023.1101341

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.